Literature DB >> 1810196

Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations.

C Chuard1, M Herrmann, P Vaudaux, F A Waldvogel, D P Lew.   

Abstract

We compared the efficacy of a long-duration (3-week) therapy of vancomycin, fleroxacin, fleroxacin plus rifampin, and vancomycin plus fleroxacin and rifampin in a recently developed rat model of chronic staphylococcal foreign-body infection. Subcutaneous tissue cages containing polymethylmethacrylate coverslips were infected with 1 x 10(5) to 5 x 10(5) CFU of methicillin-resistant Staphylococcus aureus. Three weeks later, a quantitative culturing of the fluid that had accumulated in the cages was done (mean, 6.72 log10 CFU/ml; n = 110) and treatment was initiated after randomization. The CFUs in the cage fluid were counted on days 11 and 22 and 1 week after the termination of treatment; in addition, a final culture of coverslips (surface-bound microorganisms) was performed. The three-drug therapy was significantly superior to the other treatments on day 11 (a 5.16 log10 decrease of bacterial counts versus a 2.12 log10 to 2.94 log10 decrease for vancomycin, fleroxacin, and fleroxacin plus rifampin; P less than 0.01). On day 22, count decreases were 4.16 log10 for vancomycin, 4.91 log10 for fleroxacin (vancomycin versus fleroxacin, not significant), 6.14 log10 for two-drug therapy, and 6.34 log10 for three-drug therapy (vancomycin-fleroxacin-rifampin versus fleroxacin-rifampin, not significant; fleroxacin-rifampin versus monotherapies, P less than 0.01); the numbers of CFU in most cage fluids were under the detection limit (20 CFU/ml) in combination groups. One week after the end of treatment, 92% of fluids and coverslips (detection limit, 1 CFU) were culture negative with tritherapy, 88% of fluids and 41% of coverslips were negative with bitherapy, and less than 12% of fluids and coverslips were negative with single drugs (for coverslips, P was <0.01 for vancomycin-fleroxacin-rifampin versus fleroxacin-rifampin and P was <0.001 for fleroxacin-rifampin versus the monotherapies). No mutants resistant to rifampin or fleroxacin were detected. In conclusion, antimicrobial combinations were highly effective and superior to single drugs in treating a chronic staphylococcal foreign-body infection for 3 weeks. The three-drug therapy decreased bacterial counts more rapidly than the two-drug therapy under study and appeared to be curative in most cases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1810196      PMCID: PMC245440          DOI: 10.1128/AAC.35.12.2611

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Early resistance to rifampin and ciprofloxacin in the treatment of right-sided Staphylococcus aureus endocarditis.

Authors:  P Tebas; R Martinez Ruiz; F Roman; P Mendaza; J C Rodriguez Diaz; R Daza; J M de Letona
Journal:  J Infect Dis       Date:  1991-01       Impact factor: 5.226

2.  Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin.

Authors:  R J Dworkin; B L Lee; M A Sande; H F Chambers
Journal:  Lancet       Date:  1989-11-04       Impact factor: 79.321

3.  Resistance patterns of important gram-positive pathogens.

Authors:  J F Acar; A Y Buu-Hoi
Journal:  J Antimicrob Chemother       Date:  1988-04       Impact factor: 5.790

4.  Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates. Resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S aureus colonization.

Authors:  L R Peterson; J N Quick; B Jensen; S Homann; S Johnson; J Tenquist; C Shanholtzer; R A Petzel; L Sinn; D N Gerding
Journal:  Arch Intern Med       Date:  1990-10

5.  Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus.

Authors:  J C Lucet; M Herrmann; P Rohner; R Auckenthaler; F A Waldvogel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

6.  Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; S L Barriere; L M Albrecht; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

7.  Pathogenesis of foreign body infection: description and characteristics of an animal model.

Authors:  W Zimmerli; F A Waldvogel; P Vaudaux; U E Nydegger
Journal:  J Infect Dis       Date:  1982-10       Impact factor: 5.226

8.  Resistance of Staphylococcus aureus recovered from infected foreign body in vivo to killing by antimicrobials.

Authors:  C Chuard; J C Lucet; P Rohner; M Herrmann; R Auckenthaler; F A Waldvogel; D P Lew
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

Review 9.  Gram-positive bacteria: spread and antimicrobial resistance in university and community hospitals in the USA.

Authors:  J E McGowan
Journal:  J Antimicrob Chemother       Date:  1988-04       Impact factor: 5.790

10.  Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; S L Barriere; L M Albrecht; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

View more
  33 in total

Review 1.  Infections associated with medical devices: pathogenesis, management and prophylaxis.

Authors:  Christof von Eiff; Bernd Jansen; Wolfgang Kohnen; Karsten Becker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.

Authors:  Pierre Vaudaux; Asllan Gjinovci; Manuela Bento; Dongmei Li; Jacques Schrenzel; Daniel P Lew
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

3.  Antimicrobial therapy for bone and joint infections.

Authors:  Saima Aslam; Rabih O Darouiche
Journal:  Curr Infect Dis Rep       Date:  2009-01       Impact factor: 3.725

4.  Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infection.

Authors:  O Murillo; M E Pachón; G Euba; R Verdaguer; F Tubau; C Cabellos; J Cabo; F Gudiol; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

5.  Prosthetic valve endocarditis due to Propionibacterium acnes.

Authors:  Richard van Valen; Robert A F de Lind van Wijngaarden; Nelianne J Verkaik; Mostafa M Mokhles; Ad J J C Bogers
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-04-06

6.  Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus.

Authors:  O Murillo; A Doménech; A Garcia; F Tubau; C Cabellos; F Gudiol; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

7.  Susceptibility of Staphylococcus aureus growing on fibronectin-coated surfaces to bactericidal antibiotics.

Authors:  C Chuard; P Vaudaux; F A Waldvogel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

8.  Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants.

Authors:  M Drancourt; A Stein; J N Argenson; A Zannier; G Curvale; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

9.  Bactericidal activity of the combination of levofloxacin with rifampin in experimental prosthetic knee infection in rabbits due to methicillin-susceptible Staphylococcus aureus.

Authors:  Claudette Muller-Serieys; Azzam Saleh Mghir; Laurent Massias; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

Review 10.  Recognition, management and prophylaxis of endocarditis.

Authors:  D Stamboulian; E Carbone
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.